Van ECK Associates Corp Decreases Holdings in Edwards Lifesciences Corporation $EW

Van ECK Associates Corp decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 9.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 126,258 shares of the medical research company’s stock after selling 13,722 shares during the period. Van ECK Associates Corp’s holdings in Edwards Lifesciences were worth $11,421,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $5,318,092,000. Bank of New York Mellon Corp bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth $1,274,082,000. Norges Bank purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $803,686,000. Bank of America Corp DE purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $605,397,000. Finally, Deutsche Bank AG bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $516,552,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 5,045 shares of company stock worth $457,749 in the last three months. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of a number of research reports. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Evercore restated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Mizuho raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Up 0.7%

EW stock opened at $90.86 on Tuesday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $52.32 billion, a PE ratio of 52.22, a PEG ratio of 2.37 and a beta of 0.85. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The stock has a 50-day simple moving average of $89.64 and a two-hundred day simple moving average of $85.18.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.